Point/Counterpoint: Dordaviprone for diffuse midline glioma - A landmark approval or a premature step?

Diffuse midline glioma (DMG) remains one of the most aggressive and uniformly fatal brain tumors, with a median overall survival (OS) of only 11 months and no systemic therapy yet demonstrating a meaningful survival benefit. Primarily affecting children and young adults, DMG represents an area of profound unmet clinical need where families and oncologists have faced decades of therapeutic stagnation. The recent accelerated approval by the United States (US) Food and Drug Administration (FDA) of dordaviprone (ONC201, ModeysoTM) for patients with progressive H3 K27M-altered DMG marks the first regulatory recognition of a systemic therapy for this devastating disease. The decision has generated both optimism and debate within the neuro-oncology community. For many, the approval symbolizes long-overdue progress and affirms that systemic agents can demonstrate activity in DMG. For others, it raises concerns over whether the current evidence base is sufficient to justify widespread clinical adoption. The accelerated approval pathways allow for earlier access to therapy for serious life-threatening conditions based on surrogate endpoints, such as durable objective response rates (ORRs), while mandating post-approval studies to confirm benefit. However, while approvals using data from single-arm trials can make promising therapies available to patients expeditiously, such exceptional approvals present challenges that must be carefully considered. In the case of dordaviprone, this mechanism was applied following an integrated analysis of early-phase studies (ONC006 (NCT02525692), ONC013 (NCT03295396), ONC014 (NCT03416530),1 ONC016 (NCT05392374), and ONC018 (NCT03134131))2 that demonstrated measurable radiographic and biological responses in a subset of patients. Here, we examine the scientific, clinical, and regulatory context of the dordaviprone approval through contrasting perspectives. We consider both the landmark nature of this decision and the potential risks of overinterpreting preliminary evidence, aiming to clarify what this approval means for current practice and for the future development of therapies in DMG and other brain tumors.